Gauthier M - Search Results

1

Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia.

Gauthier M, Durrieu F, Martin E, Peres M, Vergez F, Filleron T, Obéric L, Bijou F, Quillet Mary A, Ysebaert L. Gauthier M, et al. BMC Cancer. 2019 Aug 14;19(1):809. doi: 10.1186/s12885-019-5971-z. BMC Cancer. 2019. PMID: 31412798 Free PMC article.

2

[Minimal residual disease in chronic lymphocytic leukemia: A still current issue in 2018].

Gauthier M, Comont T, Vergez F, Ysebaert L. Gauthier M, et al. Bull Cancer. 2018 Nov;105(11):1042-1051. doi: 10.1016/j.bulcan.2018.07.008. Epub 2018 Sep 20. Bull Cancer. 2018. PMID: 30243477 Review. French.

3

Venetoclax with high-dose methotrexate and rituximab seem effective and well-tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report.

Beziat G, Gauthier M, Protin C, Oberic L, Lerebours F, Carlier J, Ysebaert L. Beziat G, et al. Among authors: gauthier m. Clin Case Rep. 2020 Jan 10;8(2):269-273. doi: 10.1002/ccr3.2580. eCollection 2020 Feb. Clin Case Rep. 2020. PMID: 32128171 Free PMC article.

4

Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma.

Oberic L, Delzor F, Protin C, Perriat S, Laurent C, Grand A, Canonge JM, Borel C, Gauthier M, Ysebaert L, Puisset F. Oberic L, et al. Among authors: gauthier m. J Oncol Pharm Pract. 2021 Oct;27(7):1730-1735. doi: 10.1177/1078155220968615. Epub 2020 Oct 25. J Oncol Pharm Pract. 2021. PMID: 33100177

5

Eye-catching spindle-shaped mast cells without sinister significance.

Gauthier M, Rieu JB, Laurent C, Vergez F. Gauthier M, et al. Br J Haematol. 2021 Mar;192(5):798. doi: 10.1111/bjh.17207. Epub 2020 Nov 21. Br J Haematol. 2021. PMID: 33222151 Free article. No abstract available.

6

Impact of a comprehensive geriatric assessment on decision-making in older patients with hematological malignancies.

Garric M, Sourdet S, Cabarrou B, Steinmeyer Z, Gauthier M, Ysebaert L, Beyne-Rauzy O, Gerard S, Lozano S, Brechemier D, Filleron T, Mourey L, Balardy L. Garric M, et al. Among authors: gauthier m. Eur J Haematol. 2021 May;106(5):616-626. doi: 10.1111/ejh.13570. Epub 2021 Feb 14. Eur J Haematol. 2021. PMID: 33340150

7

[Chronic lymphocytic leukemia].

Gauthier M. Gauthier M. Rev Med Interne. 2022 Jun;43(6):356-364. doi: 10.1016/j.revmed.2022.01.010. Epub 2022 Feb 17. Rev Med Interne. 2022. PMID: 35184869 French.

8

"Accelerated phase" chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies.

Lapierre L, Syrykh C, Largeaud L, Cabarrou B, Filleron T, Oberic L, Kanoun S, Coster L, Laurent C, Branco B, Gadaud N, Récher C, Brechemier D, Balardy L, Vergez F, Ysebaert L, Gauthier M. Lapierre L, et al. Among authors: gauthier m. Hematol Oncol. 2022 Oct;40(4):805-808. doi: 10.1002/hon.2985. Epub 2022 Mar 8. Hematol Oncol. 2022. PMID: 35246868 No abstract available.

9

Looking for the truth: an IGH-MYC+ lymphoid neoplasm with immature B-cell phenotype (CD34 positivity) successfully treated with Burkitt lymphoma protocol.

Gauthier M, Rieu JB, Oberic L, Vergez F. Gauthier M, et al. Ann Biol Clin (Paris). 2022 Mar 1;80(2):199-200. doi: 10.1684/abc.2022.1713. Ann Biol Clin (Paris). 2022. PMID: 35766067 English. No abstract available.

10

Vacuolated lymphocytes as initial presentation of angioimmunoblastic T-cell lymphoma.

Gauthier M, Dombrowski D, Vergnolle I, Kfoury E, Vergez F, Daniau B. Gauthier M, et al. Br J Haematol. 2023 Oct;203(2):150-151. doi: 10.1111/bjh.19030. Epub 2023 Aug 23. Br J Haematol. 2023. PMID: 37614039 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

853 results

Search Page